I am a
Home I AM A Search Login

Papers of the Week


2022


J Pediatr Pharmacol Ther


27


4

Evaluation of the Safety of Ketorolac in Postsurgical Infants Less Than Six Months of Age.

Authors

McElroy NA, Bustin A, Gattoline S
J Pediatr Pharmacol Ther. 2022; 27(4):347-351.
PMID: 35558356.

Abstract

Ketorolac-related adverse events are not yet elucidated in neonates and infants given paucity of data. The objective of this research is to determine the incidence of major bleed in postsurgical neonates and infants treated with ketorolac, and to describe characteristics of ketorolac therapy and its effect on renal function.